Products for Research Use Only
RegisterLogin

Zimlovisertib

CAT: 0804-HY-19836-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19836-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas[1][2].
CAS Number
1817626-54-2
Product Name Alternative
PF-06650833
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PF06650833.html
Purity
99.94
Solubility
DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O
Molecular Formula
C18H20FN3O4
Molecular Weight
361.37
Precautions
H315, H319, H335
References & Citations
[1]Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) : a patent review (2012-2015) . Expert Opin Ther Pat. 2016 Aug;26 (8) :917-32.|[2]Lee KL, et al. Discovery of Clinical Candidate 1-{[ (2S,3S,4S) -3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60 (13) :5521-5542.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
IRAK4

Alternative Products

CatalogName
BUP10052-01Zimlovisertib
S8531-25mgZimlovisertib (PF-06650833)

Popular Products